Compare SkyWest Inc (SKYW) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SkyWest Inc vs BIO-TECHNE Corp — how do they compare? SkyWest Inc trades at $96.26 (market cap $3.69B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: BIO-TECHNE Corp is far larger — about 3.1× SkyWest Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals.
| SKYW | TECH | |
|---|---|---|
Market Cap | $3.69B | $11.34B |
Sector | Technology | Health |
52-Week High | $115.94 | $72.48 |
52-Week Low | $78.40 | $43.31 |
Enterprise Value | $5.47B | $11.36B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SkyWest (SKYW) trades at $94.98, down 4.12% on the day, amid a bearish technical signal. The stock shows mixed earnings performance with a recent Q2 2026 miss but a Q1 beat, while maintaining solid profitability with a net margin of 9.78% and ROE of 15.34%. Valuation metrics appear attractive with a P/E of 9.44 and P/S of 0.92, below industry averages. Recent news highlights institutional interest and fleet expansion as growth drivers.
The outlook is cautiously optimistic given strong analyst support—56% buy ratings with a $112 consensus target—and robust cash flow trends. Key risks include earnings volatility, cost pressures from maintenance and fuel, and insider selling. The stock presents a value opportunity if operational execution improves, but investors should monitor quarterly results for sustained momentum.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
